News

Targeted Oncology12d
FDA Clears IND for Phase 1 Study of Lonitoclax in Relapsed/Refractory AML
Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...
FierceBiotech27d
Merck's oral PCSK9 inhibitor leader reduces cholesterol in phase 3
Merck & Co.’s ambition to get the first oral PCSK9 inhibitor to market came one step closer this morning as the pharma unveiled a pair of phase 3 wins for enlicitide decanoate in patients with ...
Morningstar26d
DeepCure Announces DC-15442 as Development Candidate, an Oral STAT6 Inhibitor with 100% in vivo inhibition of pSTAT6 and comparable efficacy to dupilumab across ... - Morningstar
DeepCure Announces DC-15442 as Development Candidate, an Oral STAT6 Inhibitor with 100% in vivo inhibition of pSTAT6 and comparable efficacy to dupilumab across disease models DeepCure Announces ...
MedPage Today25d
Early eGFR Dip Likely Doesn't Hinder SGLT2 Inhibitor's Kidney Benefits - Medpage Today
The SGLT2 inhibitor empagliflozin (Jardiance) reduced the risk of creatinine increases and acute kidney injury (AKI) even in those with an early dip in estimated glomerular filtration rate (eGFR ...
Pharm Exec27d
Phase III Trials Show Merck’s Oral PCSK9 Inhibitor Significantly Reduces LDL-Cholesterol in Hyperlipidemia
Results from the Phase III CORALreef HeFH and CORALreef AddOn trials show that enlicitide decanoate, Merck’s investigational oral PCSK9 inhibitor for adults with hyperlipidemia already on ...
ascopubs.org9d
Safety and tolerability of increasing doses of CB-839, a first-in-class, orally administered small molecule inhibitor of glutaminase, in solid tumors. - ASCO Publications
Background: Glutamine is required for the growth and survival of multiple tumor types. CB-839 is a highly selective, reversible, allosteric inhibitor of glutaminase, a choke point in the utilization ...